Notably, both THAP9 and THAP9-AS1 genes underwent amplification in breast cancer, non-small cell lung cancer, melanoma, embryonal tumor, and bone cancer but underwent “deep deletion” (indicates a deep loss, possibly a homozygous deletion) in uterine endometrioid carcinoma patients. Here, THAP9 is linked to bone cancer.